David Renwick

A year later, none of the $1.5B for rare disease has flowed to patients

• Further delays risk undermining the health and well-being of the very patients the National Strategy for Drugs for Rare Diseases was intended to assist.

Opinion | BY DAVID RENWICK | February 28, 2024

A year later, none of the $1.5B for rare disease has flowed to patients

Opinion | BY DAVID RENWICK | February 28, 2024

• Further delays risk undermining the health and well-being of the very patients the National Strategy for Drugs for Rare Diseases was intended to assist.

A year later, none of the $1.5B for rare disease has flowed to patients

Opinion | BY DAVID RENWICK | February 28, 2024

• Further delays risk undermining the health and well-being of the very patients the National Strategy for Drugs for Rare Diseases was intended to assist.

A year later, none of the $1.5B for rare disease has flowed to patients

• Further delays risk undermining the health and well-being of the very patients the National Strategy for Drugs for Rare Diseases was intended to assist.

Opinion | BY DAVID RENWICK | February 28, 2024

A year later, none of the $1.5B for rare disease has flowed to patients

Opinion | BY DAVID RENWICK | February 28, 2024

• Further delays risk undermining the health and well-being of the very patients the National Strategy for Drugs for Rare Diseases was intended to assist.

A year later, none of the $1.5B for rare disease has flowed to patients

Opinion | BY DAVID RENWICK | February 28, 2024

• Further delays risk undermining the health and well-being of the very patients the National Strategy for Drugs for Rare Diseases was intended to assist.

More Stories